Millennium Pharmaceuticals Forms Alliance with Aventis Pharma

Millennium Pharmaceuticals Forms Alliance with Aventis Pharma

Client News

On June 23, 2000, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Aventis Pharma, the pharmaceutical company of Aventis S.A. (NYSE: AVE), announced that they had formed a unique alliance. Hale and Dorr's Life Sciences Group served as counsel to Millennium in the agreement. The two companies will form an alliance to develop and commercialize drugs for the treatment of inflammatory diseases, and to develop new drug discovery technologies. The agreement includes the transfer of key elements of Millennium's technology platform to Aventis to enhance its existing capabilities, a development and commercialization collaboration in the inflammation field, and the purchase of an equity interest in Millennium by Aventis. The full agreement represents nearly $450 million in payments to and investments in Millennium by Aventis.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.